Mozzaz Named a Finalist for the 2022 Innovation Challenge in Kidney Disease by Lyfebulb and CVS Kidney Care®
March 22. 2022 | Philadelphia, PA- Mozzaz Corporation (Mozzaz) has been announced as a finalist for the 2022 Innovation Challenge: Accelerating Innovations in Kidney Disease to Improve Health Equity and Outcomes by the teams at Lyfebulb and CVS Kidney Care®, a CVS Health® (NYSE:CVS) company.
Mozzaz is one of 11 companies that will present their concept to improve kidney health to a panel of esteemed judges on May 19, 2022, for a chance to be awarded $25,000 to further their work.
At Mozzaz, we specialize in virtual care solutions for complex care programs and services. In fact, the company was founded from our own personal experiences and mission in helping individuals, their families and care teams with technology-enabled solutions for chronic illness and disabilities. Chronic Kidney Disease (CKD) is especially personal to me as I just lost an uncle a few weeks ago who was living with CKD for several years and saw the direct effects of how his life had changed and the challenges put on the family. In addition to personal experiences with CKD, our work with CVS Kidney Care in delivering virtual care solutions and a care coordination platform across diverse care teams and their patients has inspired our team to continue exploring how our technology can be leveraged to better predict, prevent, and treat CKD while removing barriers to care for improved health equity. Mozzaz’s experience and inclination for innovation to power the digital transformation of healthcare made this year’s Innovation Challenge a natural fit.
- Rini Gahir | CEO & Co-Founder | Mozzaz
Mozzaz’s vision is to create a health care industry that predicts diseases sooner, and addresses identified risk with personalized interventions and precise care. CKD is often diagnosed too late, making it hard prevent adverse health outcomes for patients, yet the disease can be slowed or even averted if diagnosed early. The Mozzaz Solution proposed for the 2022 Innovation Challenge would leverage predictive analytics to identify individuals at-risk for CKD and provide them with personalized virtual care tools. The virtual care solution would include remote patient monitoring and digital care plans with actionable alerts and interventions in addition to other useful features like video visits, messaging, and educational content. Digitizing the patient experience allows Mozzaz to tackle barriers to health equity with multiple options for language, specialized accessibility tools, omnichannel engagement, and no geographic dependency. Taking the social determinants of health (SDoH) of a population into account during the predictive analytics stage will ensure that the virtual care solution is set up for success.
The finalists, co-selected by the Lyfebulb and CVS Kidney Care teams, brought forward an array of strategic, creative, and scalable concepts to make kidney care more understandable, accessible, and equitable. The potential impact on patients and their care partners as well as the feasibility and sustainability of innovations in the market were considerations in the selection of the finalists.
Treatment options for those with advanced stages of chronic kidney disease haven’t changed in decades and the ideas brought forward as a result of this challenge are energizing. We applaud the finalists for their efforts to combat kidney disease, and we look forward to partnering with the winner to improve kidney health for everyone.
- Jesse Roach | MD, Senior Medical Director, Health Equity | CVS Kidney Care
To learn more about Mozzaz, visit Mozzaz.com, and to learn more about the Lyfebulb-CVS Kidney Care Innovation Challenge, visit Lyfebulb.com
About Mozzaz
Mozzaz is a leading provider of virtual care solutions for personalized engagement and remote patient management. With Mozzaz Adaptive Intervention Modeler (AIM™) technology, healthcare organizations can deliver personalized virtual models-of-care including: digital care plans, interventions, education, data-driven interactions, advanced machine learning for predictive and personalized experiences. The Mozzaz platform allows healthcare organizations to model clinical programs based on unique workflows from a single engagement platform. Mozzaz is built on the trusted Microsoft Azure Cloud for enterprise-ready digital health. Visit our website.
For more information contact:
Keelie Truell | Sr. Marketing Manager
(215) 325-1802 | Mozzaz Corporation
About CVS Kidney Care
CVS Kidney Care is reimagining the future of kidney health – because patients deserve care that helps them live on their own terms. Our unmatched patient insights, grounded in CVS Health’s connectivity, link data and clinical knowledge to create a personalized approach that breaks down barriers to care, including systemic barriers that have led to disparities in kidney health. Our end-to-end approach is flexible and customizable to help support a truly patient-centered experience. No matter where people are in their kidney health journey, we help them connect to an integrated network of options that make care easier to understand, more accessible, and suited to their needs.
We are changing kidney disease as we know it because the more than 37 million Americans living with chronic kidney disease deserve more than 20th century solutions. Learn more at www.cvskidneycare.com.
About Lyfebulb
Lyfebulb is an innovation accelerator that bridges the gap between patient communities and the healthcare industry by working directly with patients and care partners to generate insights and build new solutions to reduce the burden of living with chronic disease. Lyfebulb operates across 12 disease states and counting. For more information, see Lyfebulb.com, TransplantLyfe.com, IBDLyfe.com,
Instagram, LinkedIn, Twitter, Facebook, and Karin Hehenberger LinkedIn.
